Curzon Capital Limited is a London-based alternative investment adviser dedicated to structuring and distributing innovative, tax-efficient investment products primarily for promotion through the UK IFA community.

Last year we launched CFD Capital-protected Discretionary Managed Accounts. "Curzon CFDs" comprise a stockbroker managed account containing an allocation to a Contracts For Difference trading programme (30% approx) and an allocation to corporate bonds issued by UK high street banks (65% approx). The combination of these two investments provide the prospect of highly-geared returns on short term movements in a small number of the most liquid FTSE stocks together with the potential for capital protection afforded by an allocation to a highly-rated UK bank bond maturing in around 5 years time at which point it should repay an amount equivalent to the entire investment in Curzon CFDs.

We are currently advising on a private placing of shares in Trading Property Management Ltd - an exciting new business trading in discounted UK residential property. The placing aims to raise £8 million and closes on 30 April 2010.

We are also advising on a private placing of shares in a series of bio-tech companies ("SPVs") raising funds to finance the human trials of an innovative drug for the treatment for Type 2 Diabetes. Each SPV will look to raise £8 million to co-finance the clinical trials and will own the exploitation rights to a particular territory (N. America, Europe and ROW). In 2009 the market for T2D treatments was estimated to be worth US$21.9 billion. The placing closes on 30 April 2010 and the results of the testing will be known by Q1 2011 at which point the SPVs will either be sold for a significant profit multiple, or (if the trials are unsuccessful) they will have negligible value and be liquidated.

For further details of these and all our other products please contact Charlie Goldsmith or Patrick McMeekin on 020 7355 2427.